Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will host a virtual investor and analyst event on December 8, 2025 at 12:30 PM ET / 9:30 AM PT to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The presentation covers results scheduled for the 67th ASH Annual Meeting. Management and lead investigators will participate. A live webcast and replay will be available on the company website under Investors > Events and Presentations.

Event Scheduled for December 8, 2025 at 12:30 PM ET

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET / 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI^®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting.

The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When is the Kura Oncology (KURA) virtual investor event to discuss ASH 2025 data?

The event is scheduled for December 8, 2025 at 12:30 PM ET / 9:30 AM PT.

What data will Kura Oncology (KURA) discuss at the December 8, 2025 webcast?

Data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory AML.

How can investors watch the Kura Oncology (KURA) ASH 2025 event webcast?

The live webcast and replay will be available on Kura Oncology’s website under Investors > Events and Presentations.

Who will present at the Kura Oncology (KURA) virtual analyst and investor event on December 8, 2025?

The presentation will feature members of management alongside the lead investigators for the ASH 2025 data.

What topic will Kura Oncology (KURA) cover from the 67th ASH Annual Meeting on December 8, 2025?

The company will discuss ASH 2025 results for the ziftomenib, venetoclax, and azacitidine triplet regimen in AML.